Lung cancer is a serious disease that often returns or spreads after initial treatment. For many people with this condition, the cancer has grown back or spread before they can get a second chance at a cure. This study looked at a specific group of patients who had advanced non-small-cell lung cancer and had not yet received systemic treatment for their advanced disease. These patients also had a specific marker on their tumors called PD-L1, which helps the immune system fight cancer, and they had a life expectancy of at least three months. The goal was to find a better first-line treatment to keep the cancer from growing for longer.
In this large study, 531 patients were treated at 79 centers across China. Half of the patients received a new combination therapy. They got an intravenous injection of benmelstobart on day one, followed by daily oral pills of anlotinib for two weeks. The other half received a standard treatment with an intravenous injection of pembrolizumab and a placebo pill. The main goal was to see how long it took for the cancer to start growing again, known as progression-free survival.
The results showed a clear difference between the two groups. Patients on the new combination therapy lived a median of 11.0 months without their cancer growing. In contrast, patients on the standard treatment lived a median of 7.1 months. This means the new treatment delayed cancer growth by about four months on average. The study found this difference was statistically significant, meaning it was very likely a real effect of the drugs and not just random chance.
However, the new treatment came with a heavy price in terms of side effects. More than half of the patients in the new group experienced severe side effects, compared to about 29% in the standard group. The most common severe issue was high blood pressure, which affected 26% of the new group but only 3% of the standard group. Other serious issues included coughing up blood and lung inflammation. Because of these risks, doctors cannot simply switch everyone to the new drug without considering the patient's ability to handle side effects.
It is important not to get too excited about these results yet. The study only followed patients for an average of about 11 months. We do not yet know if this benefit lasts for years or if it helps patients live longer overall. More time is needed to see the full picture. Until then, this study suggests the new combination could be a potential option for some patients, but it is not a guaranteed cure. Patients should discuss these trade-offs with their doctors to decide what is right for their specific situation.